Application of group of metabolic markers in early diagnosis of metabolic syndrome

Abstract

The invention discloses an application of a group of metabolic markers in early diagnosis of a metabolic syndrome. The metabolic markers at least comprise glutamine-leucine and phosphatidyl ethanolamine PE (18:2(9Z,12Z) / P-18:0), and further comprise tyrosine or phenylalanine. In a validation set of a specific embodiment, the accuracy degree for distinguishing a health volunteer and a metabolic syndrome patient through joint use of tyrosine, phosphatidyl ethanolamine PE (18:2(9Z,12Z) / P-18:0) and glutamine-leucine reaches 80.5%, and the accuracy degree for distinguishing the health volunteer andthe metabolic syndrome patient through joint use of phenylalanine, glutamine-leucine and phosphatidyl ethanolamine PE (18:2(9Z,12Z) / P-18:0)reaches 82.6%. Therefore, the abovementioned metabolic markers have high accuracy degree for diagnosis of the metabolic syndrome, can be prepared into a metabolic syndrome diagnosis kit and are used for early diagnosis of a healthy person suffering from the metabolic syndrome.

Description

technical field [0001] The invention belongs to the field of disease detection and diagnosis, and relates to the discovery and application of disease diagnostic markers, in particular to the application of metabolic markers in the early diagnosis of metabolic syndrome and colorectal cancer. Background technique [0002] Colorectal cancer is one of the common malignant tumors and has become one of the three major cancers in China, with a prevalence rate as high as 46.8 / 100,000, and 130,000 to 160,000 new cases each year. If colorectal cancer is detected early, the 5-year survival rate of patients can reach more than 90%; if it is not detected early enough that it has metastasized to other organs or tissues, the survival rate is only about 10%. Therefore, early diagnosis of colorectal cancer is very important to improve the survival rate of colorectal cancer patients. [0003] Patients with metabolic syndrome have a significantly higher probability of developing colorectal ca...

AI Technical Summary

Problems solved by technology

In recent years, there have been many studies on serum markers of colorectal cancer, and many markers have been screened, but most of them still lack specificity and sensitivity, and few studies have verified the screened markers , because the time cost and economic cost of verification are very high, so the accuracy of the result cannot be guaranteed

Images